Study | Year | Country | N (1) | N (2) | N (3) | Percent of TP53 co-mutation | Methods of gene detection | Sample | Clinical stage | Pathological type | Detected exons of TP53 | Study type |
---|---|---|---|---|---|---|---|---|---|---|---|---|
CLCGP | 2013 | USA | 1255 | 80 | 27/53 | 33.75% | Sanger Sequencing | tissue | III, IV | NSCLC | 2–11 | Retro |
Molina-Vila | 2014 | Europe | 193 | 193 | 50/143 | 25.91% | HRM technique | tissue | IIIB, IV | NSCLC | 5–8 | Retro |
Bria E | 2015 | Italy | 18 | 18 | 7/11 | 38.89% | NGS or Sanger sequencing | tissue | IIIB, IV, recurrent | ADC | 2–11 | Retro |
Canale M | 2017 | Italy | 123 | 123 | 37/86 | 30.08% | Direct Sequencing | tissue | advanced | ADC (98.5%) | 5–8 | Retro |
Labbé C | 2017 | Canada | 105 | 60 | 24/36 | 40% | NGS or Sanger sequencing | tissue | advanced | ADC (96.19%) | 5–10/2–11 | Retro |
Vander Laan | 2017 | USA | 171 | 20 | 10/10 | 50% | Sanger sequencing | tissue | IV, recurrent | ADC | 5–8 | Retro |
Aisner | 2018 | USA | 904 | 35 | 21/14 | 60% | NGS | tissue | IV, recurrent | NSCLC | 2–11 | Pro |
Tsui DWY | 2018 | UK | 50 | 30 | 12/18 | 40% | TAm-Seq | plasma | IV | NSCLC | 5–8 | Pro |
HelenaA.Yu | 2018 | USA | 200 | 200 | 119/81 | 59.5% | NGS | tissue | IV | ADC | 2–11 | Retro |
Youjin Kim | 2018 | Korea | 200 | 75 | 43/32 | 57.33% | NGS | tissue | advanced | NSCLC | 2–11 | Retro |
Youjin Kim | 2018 | Korea | – | 82 | 50/32 | 60.98% | NGS | tissue | advanced | NSCLC | 2–11 | Retro |
Rachiglio AM | 2019 | China | 133 | 133 | 23/110 | 17.29% | NGS | tissue | advanced, metastatic | NSCLC | 2–11 | Retro |
Kron A | 2018 | Germany | 216 | 93 | 22/71 | 26.19% | NGS | tissue | IIIB, IV | ADC | 2–11 | Retro |
Kron A | 2018 | Germany | – | 33 | 11/22 | 33.33% | NGS | tissue | IIIB, IV | ADC | 2–11 | Retro |
Yu Y | 2018 | China | 52 | 35 | 21/14 | 60% | Illumina HiSeq400 platform | tissue | III, IV | ADC | 2–11 | Retro |
Christopoulos P | 2019 | Germany | 102 | 68 | 21/47 | 30.88% | NGS | tissue | IV | ADC | 2–11 | Mixed |
Song P | 2019 | China | 64 | 64 | 15/49 | 23.44% | NGS | tissue | IIIB, IV | ADC (98.4%) | 2–11 | Retro |
Study | Targeted drugs | Treatment line | Outcome | Analysis method | HR estimation | |||||||
CLCGP | EGFR-TKIs | All lines | OS | Multivariate | Calculated from raw data | |||||||
Molina-Vila | EGFR-TKIs | All lines | OS | Multivariate | Reported | |||||||
Bria E | EGFR-TKIs | First line | PFS, OS | Univariate | Reported | |||||||
Canale M | EGFR-TKIs | First line | PFS, OS | Univariate | Reported | |||||||
Labbé C | EGFR-TKIs | First line | PFS, OS | Multivariate | Reported | |||||||
Vander Laan | EGFR-TKIs | All lines | PFS, OS | Multivariate | SC | |||||||
Aisner | EGFR-TKIs | All lines | OS | Not reported | SC | |||||||
Tsui DWY | EGFR-TKIs | First line | PFS, OS | Not reported | Reported | |||||||
HelenaA.Yu | EGFR-TKIs | All lines | PFS, OS | Not reported | Calculated from raw data | |||||||
Youjin Kim | EGFR-TKIsa | First line | PFS, OS | Multivariate | Reported | |||||||
Youjin Kim | EGFR-TKIsb | second line | PFS, OS | Multivariate | Reported | |||||||
Rachiglio AM | EGFR-TKIs | First line | PFS, OS | Multivariate | Reported | |||||||
Kron A | ALK-TKIsc | All lines | PFS, OS | Multivariate | Reported | |||||||
Kron A | ALK-TKIsd | All lines | PFS, OS | Multivariate | Reported | |||||||
Yu Y | ALK-TKIs | First line | PFS | Not reported | Reported | |||||||
Christopoulos P | ALK-TKIs | All lines | PFS | Not reported | Calculated from raw data | |||||||
Song P | ALK-TKIs | All lines | PFS | univariate | Reported |